Which medication requires a new prescription before being administered via IV push to a client with type 1 diabetes?

In the context of managing diabetes, specifically with insulin therapies, certain types of insulin have specific administration guidelines. NPH insulin, classified as an intermediate-acting insulin, is typically not administered via IV push. This form of insulin is designed for subcutaneous injection rather than being delivered intravenously due to its formulation and pharmacokinetics.

If a healthcare provider deems it necessary to administer insulin intravenously—often required in acute care settings or during certain medical emergencies—a fast-acting insulin that is suitable for IV use, such as regular insulin, is preferred. Therefore, transitioning to an IV route for NPH insulin would necessitate a new prescription, as it is not standard practice to administer it in that manner.

Other options like regular insulin (10 units) and aspart insulin (18 units) can be used intravenously, while glargine insulin is a long-acting formulation that is generally not suitable for IV use either, but its scenario doesn't directly disrupt typical administration protocols as significantly as NPH does. Hence, a new prescription is mandated before using NPH insulin via IV push.